CN111053735A - Cold compress gel for treating insomnia - Google Patents
Cold compress gel for treating insomnia Download PDFInfo
- Publication number
- CN111053735A CN111053735A CN202010117232.0A CN202010117232A CN111053735A CN 111053735 A CN111053735 A CN 111053735A CN 202010117232 A CN202010117232 A CN 202010117232A CN 111053735 A CN111053735 A CN 111053735A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- cold compress
- mirtazapine
- compress gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 19
- 206010022437 insomnia Diseases 0.000 title claims abstract description 19
- 229960001785 mirtazapine Drugs 0.000 claims abstract description 39
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims abstract description 39
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 24
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960003987 melatonin Drugs 0.000 claims abstract description 24
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 18
- 229960001631 carbomer Drugs 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000007872 degassing Methods 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000935 antidepressant agent Substances 0.000 abstract description 7
- 229940005513 antidepressants Drugs 0.000 abstract description 5
- 230000001430 anti-depressive effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Abstract
The invention relates to a cold compress gel for treating insomnia, which consists of 0.5-3 parts by weight of mirtazapine, 1-5 parts by weight of melatonin, 0.1-1 part by weight of carbomer and 80-95 parts by weight of water. Mirtazapine has proven to be a safe, well tolerated and effective antidepressant. The mirtazapine and melatonin of the invention have synergistic effect in improving sleep by external application. In particular, the side effects of mirtazapine can be reduced.
Description
Technical Field
The invention relates to a cold compress gel for treating insomnia.
Background
Mirtazapine, a class of antidepressants, is known as a noradrenergic and specific 5-hydroxytryptamine antidepressant (NaSSA) which enhances both noradrenergic and 5-hydroxytryptamine neurotransmission by antagonizing the presynaptic α 2-adrenergic receptor, while blocking the postsynaptic 5-hydroxytryptamine (5-HT2 and 5-HT3) receptors.
Dosage units for oral administration of mirtazapine are generally considered to be in the form of conventional tablets. The concentration of the pharmaceutically active ingredient may range up to 15 to 45 mg mirtazapine. These known tablets are generally acceptable in terms of their pharmaceutical activity, and mirtazapine has proven to be a safe, well-tolerated and effective antidepressant. Nevertheless, as seems unavoidable in the field of antidepressant drugs, mirtazapine also needs improvement. In particular, improvements are needed in reducing side effects. For mirtazapine, these side effects mainly include appetite enhancement, weight gain, daytime sleepiness, sexual dysfunction, gastrointestinal side effects, edema, restless legs, dry mouth, excessive sedation.
More specifically, mirtazapine is also needed to further enhance its beneficial effects on cold compress.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a cold compress gel for treating insomnia, wherein the cold compress gel consists of 0.5-3 parts by weight of mirtazapine, 1-5 parts by weight of melatonin, 0.1-1 part by weight of carbomer and 80-95 parts by weight of water.
The mass ratio of the mirtazapine to the melatonin is 1: 1-4.
The cold compress gel further comprises 0.1-1 weight part of silicon dioxide.
The cold compress gel also comprises 0.1-1 weight part of ethanol.
The cold compress gel also comprises 0.1-1 weight part of preservative.
The cold compress gel also comprises 0.1-1 weight part of emulsifier.
The emulsifier is one or two of oleic acid polyoxyethylene ether and polyethylene glycol fatty acid ester. A preparation method of a cold compress gel for treating insomnia comprises the following steps:
adding 0.1-1 part by weight of carbomer into 80-95 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed;
adding 0.5-3 parts by weight of mirtazapine and 1-5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed;
packaging to obtain the cold compress gel.
The mass ratio of the mirtazapine to the melatonin is 1: 1-4.
A method for preparing cold compress gel for treating insomnia comprises adding 0.1-1 weight part of emulsifier into 80-95 weight parts of water, and stirring at high speed to obtain paste;
adding 0.1-1 weight part of silicon dioxide, 0.1-1 weight part of preservative and 0.1-1 weight part of carbomer, and stirring at high speed until the mixture is uniformly mixed;
adding 0.5-3 parts by weight of mirtazapine and 1-5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed;
adding 0.1-1 weight part of ethanol, stirring, and grinding with a grinder;
vacuumizing and degassing;
and (5) packaging to obtain the finished product.
Mirtazapine has proven to be a safe, well tolerated and effective antidepressant. Nevertheless, as seems unavoidable in the field of antidepressant drugs, mirtazapine also needs improvement. In particular, improvements are needed in reducing side effects. These side effects mainly include appetite enhancement, weight gain, edema, restless legs, dry mouth, excessive sedation.
The mirtazapine and melatonin of the invention have synergistic effect in improving sleep by external application. In particular, the side effects of mirtazapine can be reduced. Mirtazapine has unexpected technical effects when used together with melatonin.
The above-described and other features, aspects, and advantages of the present application will become more apparent with reference to the following detailed description.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below. It is to be understood that the embodiments described are only a few embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the described embodiments of the invention without any inventive step, are within the scope of protection of the invention.
Unless defined otherwise, technical or scientific terms used herein shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs. The use of "first," "second," and similar terms in the description and claims of the present application do not denote any order, quantity, or importance, but rather the terms are used to distinguish one element from another. Also, the use of the terms "a" or "an" and the like do not denote a limitation of quantity, but rather denote the presence of at least one.
A cold compress gel for treating insomnia, which consists of 0.5-3 parts by weight of mirtazapine, 1-5 parts by weight of melatonin, 0.1-1 part by weight of carbomer and 80-95 parts by weight of water.
The mass ratio of the mirtazapine to the melatonin is 1: 1-4.
The cold compress gel further comprises 0.1-1 weight part of silicon dioxide.
The cold compress gel also comprises 0.1-1 weight part of ethanol.
The cold compress gel also comprises 0.1-1 weight part of preservative.
The cold compress gel also comprises 0.1-1 weight part of emulsifier.
The emulsifier is one or two of oleic acid polyoxyethylene ether and polyethylene glycol fatty acid ester. A preparation method of a cold compress gel for treating insomnia comprises the following steps:
adding 0.1-1 part by weight of carbomer into 80-95 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed;
adding 0.5-3 parts by weight of mirtazapine and 1-5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed;
packaging to obtain the cold compress gel.
The mass ratio of the mirtazapine to the melatonin is 1: 1-4.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Preparation of cold compress gel 1:
adding 0.5 part by weight of carbomer into 90 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed; adding 1 weight part of mirtazapine and 3 weight parts of melatonin, and stirring at a high speed until the mixture is uniformly mixed to obtain the cold compress gel.
Preparation of cold compress gel 2:
adding 0.5 part by weight of carbomer into 90 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed; adding 3 parts by weight of mirtazapine and 1.5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed to obtain the cold compress gel.
Preparation of cold compress gel 3:
adding 0.5 part by weight of carbomer into 90 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed; adding 0.5 weight part of mirtazapine and 3 weight parts of melatonin, and stirring at a high speed until the mixture is uniformly mixed to obtain the cold compress gel.
Test objects: each group had 20 subjects to be treated (10 males and 10 females), and all subjects completed the trial. The cold compress gel of the invention is used before sleeping every day (the mass ratio of mirtazapine to melatonin is 1: 0.5, 1: 3 and 1: 6 respectively, and the amount of mirtazapine in the cold compress gel is 60 mg). The duration of treatment was 90 days, and the 90-day weight change and sleep-aiding effect of the test subjects were measured. If a subject is not therapeutically effective, the two single doses are administered to the subject at least two weeks apart. Through experiments, the mass ratio of mirtazapine to melatonin is 1: the subject of 3 had similar weight changes as placebo at 0.5% and 0.8%, respectively, while the other mass ratios had larger changes at 8.3% and 9.4%, respectively, which are closer to the data of about 10% for mirtazapine disclosed. According to the data fed back by the test subjects, as with the mirtazapine tablets, the mass ratio of mirtazapine to melatonin of the invention is 1: 0.5, 1: 3, 1: 6 has good curative effect on helping sleep.
While there have been shown and described what are at present considered the fundamental principles and essential features of the invention and its advantages, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing exemplary embodiments, but is capable of other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and the description is given here only for clarity, and those skilled in the art should integrate the description, and the embodiments may be combined appropriately to form other embodiments understood by those skilled in the art.
Claims (10)
1. The cold compress gel for treating insomnia is characterized by comprising 0.5-3 parts by weight of mirtazapine, 1-5 parts by weight of melatonin, 0.1-1 part by weight of carbomer and 80-95 parts by weight of water.
2. The cold compress gel for treating insomnia according to claim 1, wherein the mass ratio of mirtazapine to melatonin is 1: 1-4.
3. The cold compress gel for treating insomnia according to claim 1, further comprising 0.1-1 parts by weight of silicon dioxide.
4. The cold compress gel for treating insomnia according to claim 1, further comprising 0.1-1 parts by weight of ethanol.
5. The cold compress gel for treating insomnia according to claim 1, further comprising 0.1-1 parts by weight of a preservative.
6. The cold compress gel for treating insomnia according to claim 1, further comprising 0.1-1 parts by weight of an emulsifier.
7. The cold compress gel for treating insomnia according to claim 6, wherein said emulsifier is one or two selected from polyoxyethylene oleate, polyethylene glycol fatty acid ester.
8. A preparation method of cold compress gel for treating insomnia is characterized by comprising the following steps:
adding 0.1-1 part by weight of carbomer into 80-95 parts by weight of water, and stirring at high speed until the carbomer is uniformly mixed;
adding 0.5-3 parts by weight of mirtazapine and 1-5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed;
packaging to obtain the cold compress gel.
9. The preparation method of the cold compress gel for treating insomnia as claimed in claim 8, wherein the mass ratio of mirtazapine to melatonin is 1: 1-4.
10. A preparation method of cold compress gel for treating insomnia is characterized by comprising the following steps:
adding 0.1-1 weight part of emulsifier into 80-95 weight parts of water, and stirring at high speed to form paste;
adding 0.1-1 weight part of silicon dioxide, 0.1-1 weight part of preservative and 0.1-1 weight part of carbomer, and stirring at high speed until the mixture is uniformly mixed;
adding 0.5-3 parts by weight of mirtazapine and 1-5 parts by weight of melatonin, and stirring at high speed until the mixture is uniformly mixed;
adding 0.1-1 weight part of ethanol, stirring, and grinding with a grinder;
vacuumizing and degassing;
packaging to obtain the cold compress gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010117232.0A CN111053735A (en) | 2020-02-25 | 2020-02-25 | Cold compress gel for treating insomnia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010117232.0A CN111053735A (en) | 2020-02-25 | 2020-02-25 | Cold compress gel for treating insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111053735A true CN111053735A (en) | 2020-04-24 |
Family
ID=70307721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010117232.0A Pending CN111053735A (en) | 2020-02-25 | 2020-02-25 | Cold compress gel for treating insomnia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111053735A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262260A (en) * | 2021-06-05 | 2021-08-17 | 亳州益智健康产业有限公司 | Cold compress gel for treating insomnia |
| CN116139070A (en) * | 2022-12-23 | 2023-05-23 | 杭州健崃生物科技有限公司 | Sleep-aiding cold compress gel and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552428A (en) * | 1992-06-24 | 1996-09-03 | Instituto Farmacologico Lombardo-Iflo, S.A.S. | Compounds effective in the treatment of circadian rhythms and related disorders, the novel pharmaceutical preparations and novel method of application |
| US5891903A (en) * | 1996-12-06 | 1999-04-06 | Societe L'oreal S.A. | Use of melatonin in a composition for stabilizing hydrophilic gelling polymers |
| CN1395487A (en) * | 2000-02-11 | 2003-02-05 | 阿克佐诺贝尔公司 | The use of mirtazapine for treatment of sleep disorders |
| CN1942191A (en) * | 2004-04-21 | 2007-04-04 | 奥尔加侬股份有限公司 | Pharmaceutical composition comprising a salt of mirtazapine |
| US20130253449A1 (en) * | 2010-12-07 | 2013-09-26 | Yutoku Pharmaceutical Industries Co., Ltd. | Noradrenergic and specific serotonergic antidepressant-containing transdermal patch |
-
2020
- 2020-02-25 CN CN202010117232.0A patent/CN111053735A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552428A (en) * | 1992-06-24 | 1996-09-03 | Instituto Farmacologico Lombardo-Iflo, S.A.S. | Compounds effective in the treatment of circadian rhythms and related disorders, the novel pharmaceutical preparations and novel method of application |
| US5891903A (en) * | 1996-12-06 | 1999-04-06 | Societe L'oreal S.A. | Use of melatonin in a composition for stabilizing hydrophilic gelling polymers |
| CN1395487A (en) * | 2000-02-11 | 2003-02-05 | 阿克佐诺贝尔公司 | The use of mirtazapine for treatment of sleep disorders |
| CN1942191A (en) * | 2004-04-21 | 2007-04-04 | 奥尔加侬股份有限公司 | Pharmaceutical composition comprising a salt of mirtazapine |
| US20130253449A1 (en) * | 2010-12-07 | 2013-09-26 | Yutoku Pharmaceutical Industries Co., Ltd. | Noradrenergic and specific serotonergic antidepressant-containing transdermal patch |
Non-Patent Citations (1)
| Title |
|---|
| 刘绍贵: "《中成药购药用药指南》", 31 July 2007, 湖南科学技术出版社 , pages: 191 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262260A (en) * | 2021-06-05 | 2021-08-17 | 亳州益智健康产业有限公司 | Cold compress gel for treating insomnia |
| CN116139070A (en) * | 2022-12-23 | 2023-05-23 | 杭州健崃生物科技有限公司 | Sleep-aiding cold compress gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1248613B1 (en) | Clonidine preparations | |
| US8883830B2 (en) | Topical therapy for the treatment of migraines, muscle sprains, muscle spasms, spasticity and related conditions | |
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| FI117616B (en) | Pharmaceutical composition containing the ACE inhibitor ramipril and a dihydropyridine compound | |
| EP1435945B1 (en) | Topical migraine therapy | |
| CN111053735A (en) | Cold compress gel for treating insomnia | |
| EP1210076A2 (en) | Drug therapy of the restless leg syndrome | |
| JP2009542657A5 (en) | ||
| EP4218756A1 (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| US20020155136A1 (en) | Medicine containing yohimbine and arginine for treating erectile dysfunction | |
| EA027350B1 (en) | Method for treating or preventing hot flashes and night sweats in menopausal women | |
| JP2005537307A (en) | Use of reboxetine for the treatment of hot flashes | |
| Jasonni et al. | Vaginal bromocriptine in hyperprolactinemic patients and puerperal women | |
| JPH0436243A (en) | Hypnotic sedative | |
| US20230210779A1 (en) | Controlled-release tablet of ibuprofen and method for preparing same | |
| Saul et al. | Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules | |
| KR101690765B1 (en) | Transdermal formulation comprising antifungal agent | |
| CA2946701C (en) | Rivaroxaban containing compositions and melt extrusion methods for preparing the same | |
| WO2021059283A1 (en) | Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions | |
| JP4162735B2 (en) | Rectal administration formulation containing serotonin receptor antagonist | |
| TW201806599A (en) | Dosing regimens for fast onset of antidepressant effect | |
| RU2003106417A (en) | APPLICATION OF A VITAMIN COMBINATION FOR TREATMENT OF PRIMARY HEAD PAIN | |
| CN111588694A (en) | Liquid composition containing phenylephrine hydrochloride and preparation and application thereof | |
| CN108307631B (en) | Clonidine and/or clonidine derivatives for the prevention and/or treatment of adverse side effects of chemotherapy | |
| WO2022043952A1 (en) | Low dose topical composition comprising triamcinolone acetonide or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |